Novartis has announced the opening of a new facility for the manufacturing of radiopharmaceutical Pluvicto, a nuclear medicine therapy for prostate cancer. The facility, which is the company's largest and most advanced of its kind, has received approval from the FDA. Pluvicto has faced challenges in its supply chain, resulting in significant delays in patient care. However, Novartis has increased its supply and the FDA has declared the drug shortage resolved. The new facility, located in Indianapolis, will improve access for patients and treatment centers and hopefully prevent future shortages.
Mon, 08 Jan 2024 23:39:24 GMT | Health Imaging